Printer Friendly

Company's stem cells protect cardio tissue.

NEW YORK, N.Y., September 29, 2015 -- Mesoblast Limited (USOTC:MBLTY) said that additional Phase 2 trial results of its lead product candidate for the treatment of chronic heart failure (CHF) showed that its mesenchymal precursor cell (MPC) therapy had the greatest cardioprotective effect in the subset of patients with more advanced heart failure.

A post hoc analysis was performed in 30 patients from the Phase 2 trial who had been randomized to receive either placebo or a single administration of 150 million MPCs (MPC-150-IM).

The results suggest that patients with advanced heart failure may be an optimal target population for treatment with Mesoblast's MPC therapy.

The objective of the analysis was to evaluate the efficacy of MPC-150-IM in patients with advanced heart failure, as defined by substantial baseline left ventricular (LV) contractile abnormality (LV end systolic volume, LVESV, greater than 100 ml).

LVESV greater than 100 ml is more than three standard deviations above normal LVESV and is a predictor of poor long-term outcomes in patients with CHF. A further sensitivity analysis across every decile in baseline LVESV between 70 ml and 120 ml confirmed the findings seen in the stratification using a LVESV greater than 100 ml. Cardiac remodeling by echocardiography at baseline and 6 months, time to first heart failure-related major adverse cardiovascular event (HF-MACE) by Kaplan-Meier analysis and incidence of total (recurrent) HF-MACE over 36 months were assessed.

Key findings:

* control patients with baseline LVESV greater than 100 ml had the greatest deterioration (adverse remodeling) over 6 months in terms of worsening in both LVESV and left ventricular end diastolic volume (LVEDV), and loss of left ventricular ejection fraction (LVEF)

* over a 6 month follow-up period, the 150 million MPC dose resulted in placebo-corrected significant reductions in LVESV of 57 ml (p equals 0.007) and LVEDV of 54 ml (p equals 0.004), and an increase in LVEF of 8.1 absolute percentage points (p equals 0.068) in patients with baseline LVESV greater than 100 ml

* all of the HF-MACE seen over 36 months in the Phase 2 trial occurred in control patients with baseline LVESV greater than 100 ml; the annualized HF-MACE rate was 24 percent in this group, with an overall 71 percent HF-MACE rate over 36 months

* in contrast, no HF-MACE were seen over the entire 36 months in 150 million MPC-treated patients with baseline LVESV greater than 100 ml (p equals 0.0007 when analyzed by Kaplan-Meier time-to-first-event analysis and p is less than 0.0001 by incidence analysis for total/recurrent HF-MACE, 0 versus 11 events).

Key conclusions:

* baseline LVESV greater than 100 ml identified a rapidly deteriorating sub-group of CHF patients with LV systolic dysfunction who experience a high rate of adverse outcomes

* in these patients, a single administration of 150 million MPCs resulted in a significant cardio-protective effect and prevention of any HF-MACE over 36 months of follow up

* patients with baseline LVESV greater than 100 ml may be an optimal target group for the potential cardioprotective benefits of MPC therapy.

An ongoing Phase 3 trial, using a time-to-first-event analysis of HF-MACE as the primary endpoint, is being conducted in 1,165 patients by Mesoblast's development and commercial partner, Teva Pharmaceutical Industries Ltd, across multiple sites in North America to investigate the use of MPC-150-IM in patients with advanced CHF.

The Phase 3 trial is enriched for patients with high baseline levels of NT-proBNP and a heart failure hospitalization within the last nine months, two inclusion criteria known to predict adverse outcomes in CHF. This enrichment is expected to result in the majority of enrolled patients having LV systolic dysfunction, baseline LVESV greater than 100 ml and high rates of HF-MACE.

Following recent discussions with the FDA, an interim analysis will be performed when 50 percent of the HF-MACE have occurred which will include a test for superiority allowing for the possibility of stopping of the trial early based on overwhelming efficacy.

CHF is characterized by an enlarged heart and insufficient blood flow to the organs and extremities of the body. The condition affects two percent of the adult population of the United States.

COPYRIGHT 2015 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:In The Clinic: Heart Failure
Publication:Stem Cell Research News
Date:Oct 12, 2015
Previous Article:SanBio recruiting patients to test regenerative treatment.
Next Article:Phase 2 update on ALS cell therapy.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters